Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

Minoru Nakamura; Hisayoshi Kondo; Tsuyoshi Mori; Atsumasa Komori; Mutsumi Matsuyama; Masahiro Ito; Yasushi Takii; Makiko Koyabu; Terufumi Yokoyama; Kiyoshi Migita; Manabu Daikoku; Seigo Abiru; Hiroshi Yatsuhashi; Eiichi Takezaki; Naohiko Masaki; Kazuhiro Sugi; Koichi Honda; Hiroshi Adachi; Hidehiro Nishi; Yukio Watanabe; Yoko Nakamura; Masaaki Shimada; Tatsuji Komatsu; Akira Saito; Takeo Saoshiro; Hideharu Harada; Takeshi Sodeyama; Shigeki Hayashi; Akihide Masumoto; Takehiro Sando; Tetsuo Yamamoto; Hironori Sakai; Masakazu Kobayashi; Toyokichi Muro; Michiaki Koga; Zakera Shums; Gary L. Norman; Hiromi Ishibashi

doi:10.1002/hep.21472

Abstract

These results indicate 2 different progression types in PBC, hepatic failure type and portal hypertension type progression, which may be represented by positive-anti-gp210 and positive-anticentromere antibodies, respectively.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nakamura et al. (2006) studied this question.

synapsesocial.com/papers/69dbe40f5b363cdf1c836292 https://doi.org/10.1002/hep.21472

View Full Paper

Ask AI

Bookmark

Share

Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

Abstract

Discussion

Cite This Study

Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

Abstract

Discussion

Cite This Study

Keep reading

Keep reading